Clinical Trial Update: Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated the maximum tolerated dose of lapatinib in combination with carboplatin for recurrent ovarian cancer. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Carboplatin (Paraplatin) (carboplatin)
• Lapatinib (Tykerb) (lapatinib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Ovarian Cancer | Phase 1 | Status: TERMINATED